BioNTech's Pipeline Advances at ASCO, Yet Berlin's Reform and Market Doubts Keep the Stock Grounded

For a company presenting more than two dozen clinical studies at one of oncology's biggest gatherings, the market reaction could hardly have been more muted. BioNTech's ASCO display in Chicago was broad in scope — yet the stock barely budged, trading at €76.45, just a hair above the prior close. The disconnect highlights a deepening tension: the Mainz-based biotech is building an impressive cancer pipeline, but investors are demanding proof that it will translate into revenue, while a domestic political battle threatens to undercut those ambitions before the first oncology product reaches the German market.

The centerpiece of BioNTech's ASCO presence was Gotistobart, the CTLA-4 antibody developed with OncoC4. New Phase 2 data from the PRESERVE-004 study showed the combination of Gotistobart plus Pembrolizumab produced durable tumor shrinkage and clinically meaningful overall survival in heavily pretreated patients with platinum-resistant ovarian cancer, with a manageable safety profile. It is a notoriously difficult treatment setting, and a chemo-free combination could gain commercial traction — but only if later trials confirm the signal. BioNTech framed the data as building the evidence base, not as a submission for approval.

Alongside immuno-oncology, the company pushed its antibody-drug conjugate strategy. A poster detailed the Phase 3 FERN-EC-01 study testing Trastuzumab Pamirtecan (BNT323/DB-1303) against physician's-choice chemotherapy in previously treated HER2-expressing recurrent endometrial cancer. BioNTech and partner DualityBio plan to file a Biologics License Application in 2026, subject to regulatory feedback. That gives the equity a different near-term narrative from the lung-cancer data that had dominated recent headlines. In total, BioNTech presented more than 25 Phase 2 and Phase 3 studies at ASCO, including 13 ongoing pivotal trials.

The stock's technical picture, however, tells a different story. At €76.45, the shares are roughly 7% lower year-to-date and more than 21% lower over twelve months. The 52-week high of €105.80, reached in January, sits nearly 28% above the current level. Both the 50-day moving average of €81 and the 200-day average of around €86 are well above the stock, indicating the ASCO presentations failed to break the downward trend. Financially, the company is not in distress: it ended the first quarter with €16.8 billion in cash and securities, generated €118.1 million in revenue, and posted a net loss of €531.9 million. Full-year revenue guidance stands at €2.0–2.3 billion.

Should investors sell immediately? Or is it worth buying BioNTech?

What complicates the outlook further is not clinical risk but political risk in BioNTech's home market. The German government is pushing the GKV-Beitragssatzstabilisierungsgesetz (GKV-BStabG), a sweeping healthcare cost-containment bill that aims to save nearly €20 billion by 2027 and more than €42 billion by 2030 through new pricing rules and mandatory rebates. BioNTech has joined a growing industry coalition protesting the reforms, and Eli Lilly has already signaled it will halve its planned €2.5 billion investment in Germany, cutting a large chunk of 1,000 planned jobs. For BioNTech, the stakes are especially high: favorable reimbursement conditions will be critical once its first cancer therapies reach the German market. The law is expected to pass before the summer break and take effect in January 2027.

Parallel to the legislative fight, BioNTech is pressing ahead with a deep restructuring of its manufacturing footprint. It will close three German sites — Idar-Oberstein, Marburg, and Tübingen — along with a facility in Singapore by the end of 2027, affecting up to 1,860 jobs. Annual savings from 2029 onward are expected to reach roughly €500 million, funds that will help finance the oncology pivot. Critics argue the timing is unfortunate: Germany is dismantling biotech infrastructure while simultaneously worsening investment conditions.

Analyst sentiment reflects the uncertainty. UBS upgraded the stock from Neutral to Buy after the ASCO presentations, lifting its price target from $117 to $135, citing greater confidence in the late-stage pipeline following clinical data on Pumitamig and Gotistobart. Bernstein's Jeffrey Walch struck a more cautious note, initiating coverage with a Hold rating and a $96 target — implying limited upside from current levels. BioNTech also strengthened its board for the oncology era at the May shareholder meeting, electing Iris Löw-Friedrich and Susanne Schaffert, both with deep experience in clinical development and cancer-drug commercialization.

BioNTech at a turning point? This analysis reveals what investors need to know now.

At the end of the day, the stock's revaluation will depend on whether Gotistobart, Trastuzumab Pamirtecan, and the mRNA cancer immunotherapies can progress from ongoing trials to actual approvals and sales. ASCO gave investors a broader view of the pipeline's breadth. What it did not deliver was evidence that breadth will generate revenue — and the home-market headwinds from Berlin only add to the challenge.

Ad

BioNTech Stock: New Analysis - 4 June

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECHS | boerse | 69482065 |